Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction

Area of Science:

• Pediatric Hematology
• Transplant Immunology

Background:

• Allogeneic stem cell transplantation (SCT) is curative for pediatric nonmalignant diseases but associated with high morbidity and mortality.
• Conventional conditioning regimens are often precluded by severe organ dysfunction in these patients.
• Nonmyeloablative SCT (NMSCT) presents a potentially less toxic alternative.

Purpose of the Study:

• To evaluate the safety and efficacy of a fludarabine-based NMSCT regimen in pediatric patients with nonmalignant diseases.
• To assess engraftment, disease resolution, and toxicity in this high-risk population.

Main Methods:

• Six pediatric patients with nonmalignant diseases received NMSCT.
• Conditioning involved fludarabine/melphalan, with ATG for haploidentical grafts.
• Graft-versus-host disease (GVHD) prophylaxis included tacrolimus and methotrexate, with prednisolone for haploidentical grafts.
• Hematopoietic stem cells were not T-cell depleted or purged.

Main Results:

• Five of six patients (83%) survived with complete disease resolution at a median of 19 months post-SCT.
• One patient died of bacteremia prior to engraftment.
• Three patients achieved complete donor chimerism; two had stable mixed chimerism.
• Short-term toxicities were minimal, with no cases of acute or chronic GVHD observed.
• Adequate engraftment was achieved despite severe pre-transplant organ dysfunction.

Conclusions:

• A fludarabine-based NMSCT regimen is a viable and effective approach for children with nonmalignant diseases.
• This strategy demonstrates acceptable toxicity and successful engraftment, even in patients with significant organ dysfunction.
• NMSCT offers a promising alternative to conventional SCT for this challenging patient group.